

# **Acerus Pharmaceuticals Corp (ASP) - Financial and Strategic SWOT Analysis Review**

<https://marketpublishers.com/r/A42994DC120EN.html>

Date: December 2021

Pages: 53

Price: US\$ 125.00 (Single User License)

ID: A42994DC120EN

## **Abstracts**

Acerus Pharmaceuticals Corp (ASP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

## Highlights

Acerus Pharmaceuticals Corp (Acerus), formerly Trimel Pharmaceuticals Corporation develops, manufactures, markets and distributes novel innovative branded products. It focuses in the therapeutic areas of women's health (female sexual dysfunction, hormone replacement therapy) and men's health (urology). The company's marketed products include Estrace, for menopausal symptoms and Natesto, a testosterone for male hypogonadism. Acerus pipeline products include Tefina, Avanafil, Elegant and Lidbree indicated for various health issues related to men and women. The company sells products through its salesforce in Canada and licensed distributors in the US and other countries. The company is headquartered in Mississauga, Ontario, Canada.

### Acerus Pharmaceuticals Corp Key Recent Developments

Nov 09,2021: Acerus Reports Fiscal Third Quarter Financial Results

Aug 12,2021: Acerus reports acceptance of part 36 settlement offer in recipharm litigation

Aug 10,2021: Acerus Reports Fiscal 2021 Second Quarter Financial Results

Jul 12,2021: Acerus provides update on litigation with Recipharm

Jun 14,2021: Acerus Announces Voting Results for the 2021 Annual Meeting

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

**Note:** Some sections may be missing if data is unavailable for the company

## Contents

### **SECTION 1 - ABOUT THE COMPANY**

Acerus Pharmaceuticals Corp - Key Facts  
Acerus Pharmaceuticals Corp - Key Employees  
Acerus Pharmaceuticals Corp - Key Employee Biographies  
Acerus Pharmaceuticals Corp - Major Products and Services  
Acerus Pharmaceuticals Corp - History  
Acerus Pharmaceuticals Corp - Company Statement  
Acerus Pharmaceuticals Corp - Locations And Subsidiaries  
Head Office  
Other Locations & Subsidiaries

### **SECTION 2 – COMPANY ANALYSIS**

Company Overview  
Acerus Pharmaceuticals Corp - Business Description  
R&D Overview  
Acerus Pharmaceuticals Corp - Corporate Strategy  
Acerus Pharmaceuticals Corp - SWOT Analysis  
SWOT Analysis - Overview  
Acerus Pharmaceuticals Corp - Strengths  
Acerus Pharmaceuticals Corp - Weaknesses  
Acerus Pharmaceuticals Corp - Opportunities  
Acerus Pharmaceuticals Corp - Threats  
Acerus Pharmaceuticals Corp - Key Competitors

### **SECTION 3 – COMPANY FINANCIAL RATIOS**

Financial Ratios - Capital Market Ratios  
Financial Ratios - Annual Ratios  
Performance Chart  
Financial Performance  
Financial Ratios - Interim Ratios  
Financial Ratios - Ratio Charts

### **SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES**

Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021

Acerus Pharmaceuticals Corp, Recent Deals Summary

## **SECTION 5 – COMPANY’S RECENT DEVELOPMENTS**

Nov 09, 2021: Acerus Reports Fiscal Third Quarter Financial Results

Aug 12, 2021: Acerus reports acceptance of part 36 settlement offer in recipharm litigation

Aug 10, 2021: Acerus Reports Fiscal 2021 Second Quarter Financial Results

Jul 12, 2021: Acerus provides update on litigation with Recipharm

Jun 14, 2021: Acerus Announces Voting Results for the 2021 Annual Meeting

Mar 11, 2021: Acerus Reports Fourth Quarter and Full Year 2020 Financial Results

Mar 04, 2021: Acerus to Report 2020 Financial Results and Host Investor Call

Nov 03, 2020: Acerus reports fiscal third quarter financial results

Sep 14, 2020: Acerus announces addition of US commercial leader

Aug 11, 2020: Acerus reports fiscal 2020 second quarter financial results

## **SECTION 6 – APPENDIX**

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Acerus Pharmaceuticals Corp, Key Facts  
Acerus Pharmaceuticals Corp, Key Employees  
Acerus Pharmaceuticals Corp, Key Employee Biographies  
Acerus Pharmaceuticals Corp, Major Products and Services  
Acerus Pharmaceuticals Corp, History  
Acerus Pharmaceuticals Corp, Subsidiaries  
Acerus Pharmaceuticals Corp, Key Competitors  
Acerus Pharmaceuticals Corp, Ratios based on current share price  
Acerus Pharmaceuticals Corp, Annual Ratios  
Acerus Pharmaceuticals Corp, Annual Ratios (Cont...1)  
Acerus Pharmaceuticals Corp, Annual Ratios (Cont...2)  
Acerus Pharmaceuticals Corp, Interim Ratios  
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021  
Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021  
Acerus Pharmaceuticals Corp, Recent Deals Summary  
Currency Codes  
Capital Market Ratios  
Equity Ratios  
Profitability Ratios  
Cost Ratios  
Liquidity Ratios  
Leverage Ratios  
Efficiency Ratios

## List Of Figures

### LIST OF FIGURES

Acerus Pharmaceuticals Corp, Performance Chart (2016 - 2020)

Acerus Pharmaceuticals Corp, Ratio Charts

Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Acerus Pharmaceuticals Corp, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021



## I would like to order

Product name: Acerus Pharmaceuticals Corp (ASP) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/A42994DC120EN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A42994DC120EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970